Drugs / L-Lysine HCl-L-Arginine HCl
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT06379217 Background | Jul 2024 → Sep 2026 overdue | prostate neuroendocrine neoplasm | Novartis Pharmaceuticals | Active not recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | L-Lysine HCl-L-Arginine HCl | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06379217 ↗ |